LOS ANGELES, Nov. 4, 2025 /PRNewswire/ -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics designed to restore synapses to improve health in the ...
VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology in ALS VectorY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results